News - New Science Ventures

January 12, 2021

New Science Ventures announces merger of its portfolio company Achronix with ACE Convergence

New York (NY, US), London (UK), January 12, 2021 – New Science Ventures LLC (“NSV”), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, today announces the merger of its portfolio company, Achronix Semiconductor Corporation (“Achronix”), with ACE Convergence Acquisition Corp. NSV

January 8, 2021

NorthSea Therapeutics reports Positive Phase 2b interim results for icosabutate in NASH patients

Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile Interim readout based on the first 90 patients treated for 16 weeks Once-daily oral icosabutate showed dose-dependent, significant, and clinically meaningful improvements in all liver function chemistry, and inflammatory and fibrotic biomarkers with a remarkable

December 9, 2020

Resolve Therapeutics announces clinically meaningful improvement in patients with Systemic lupus erythematosus in Phase 2a clinical trial

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced results from its Phase 2a study of RSLV-132 in patients with Systemic lupus erythematosus (SLE). Sixty-six patients diagnosed with SLE and a CLASI score of ≥ 10 at screening were enrolled into the study at 19 clinical

December 3, 2020

Resolve Therapeutics publishes positive Sjogren’s syndrome clinical trial results

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced publication of results from its Phase 2 study of RSLV-132 for the treatment of primary Sjogren’s syndrome (pSS). The work was published in the leading rheumatology journal, Arthritis and Rheumatology (doi.org/10.1002/art.41489). The Phase 2 study demonstrated a

November 20, 2020

NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline

NST becomes a multi-asset clinical development company, beyond NASH Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control A third clinical development program, SEFA 6179, for treating Intestinal Failure- Associated Liver Disease (IFALD) will start Phase 1 studies

September 28, 2020

ProterixBio Announces Commercial Availability of a Semi-Quantitative COVID-19 Antibody Test

Billerica, MA, September 29, 2020: ProterixBio, Inc. announced today commercial availability of the SARS-CoV-2 (RBD) IgG Antibody test, a semi-quantitative COVID-19 serology assay. It is being offered as a testing service through ProterixBio’s high-complexity clinical testing laboratory. Validation results demonstrated a Positive Percent Agreement (PPA) of 100% for samples acquired

September 2, 2020

Amarisoft and Dali Wireless Collaborate to Deliver Open RAN Based 4G and 5G Solutions

Interoperability and co-marketing initiatives will bring new options for enterprises, and mobile network operators deploying in-building cellular solutions Menlo Park, California and Paris, France – February 11, 2020 – Dali Wireless, a global leader in wireless fronthaul innovation for virtual RAN, and Amarisoft, a pioneer in software centric 4G LTE

July 1, 2020

ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital

Billerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by researchers at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University which is a joint

June 25, 2020

Oppilan Pharma Announces Positive Phase 1 Data for its Ulcerative Colitis Drug OPL-002 at Digestive Disease Week 2020 Virtual Scientific Program

Potential best-in-class profile for an oral sphingosine-1-phosphate receptor modulator – Dose-dependent reduction in circulating lymphocytes –– Rapid lymphocyte recovery after cessation of dosing –– Phase 2 study in ulcerative colitis patients in 4Q 2020 – ENCINITAS, California and Cambridge, United Kingdom, June 23, 2020 – Oppilan Pharma, Ltd., a clinical-stage

May 5, 2020

Zoll TherOx Receives CE Mark Approval for Supersaturated Oxygen Therapy

View Full Press Release >>

April 6, 2020

FDA Approves Next-Generation ZOLL® TherOx System for Widowmaker Heart Attack Patients First

View Full Press Release >>

March 5, 2020

Perceptimed Founder Jacobs To Speak At Bio2device Group Event

PERCEPTIMED FOUNDER JACOBS TO SPEAK AT BIO2DEVICE GROUP EVENT MOUNTAIN VIEW, CA – April 25, 2014 – “Preventing Drug-Related Patient Injury and Death with Advanced, Cost-Effective Technology” is the topic Alan Jacobs, M.D., Ph.D., CEO and founder of PerceptiMed, will address at the Bio2Device lecture. The lecture will take place